Zacks Investment Research downgraded shares of MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 (NYSEARCA:MOR) from a buy rating to a hold rating in a research report report published on Saturday morning, Zacks.com reports.

According to Zacks, “MorphoSys AG is a biopharmaceutical company. It develops treatment for cancer, inflammations and autoimmune diseases. The company’s proprietary portfolio consists of MOR208, MOR202, MOR103, MOR106 and MOR107. Its partnered programs lighthouse project includes Tremfya(R) and Gantenerumab. MorphoSys AG is based in Planegg, Germany. “

Separately, Guggenheim assumed coverage on shares of MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 in a research report on Wednesday, November 27th. They set a buy rating on the stock.

MOR stock opened at $33.04 on Friday. The firm’s 50 day moving average price is $34.81 and its 200-day moving average price is $29.99. MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 has a one year low of $22.46 and a one year high of $37.96.

Featured Article: Penny Stocks

Get a free copy of the Zacks research report on MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 (MOR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 and related companies with MarketBeat.com's FREE daily email newsletter.